In this Issue
The next act in medical glaucoma management.
By Steven D. Vold, MD
By Nisha Chadha, MD, and Timothy P. Fox, MD
Antivascular endothelial growth factor agents have dramatically changed the early management of neovascular glaucoma.
By Mark Slabaugh, MD, and Matthew Ohr, MD
MY MOST DIFFICULT CASE
Patchless glaucoma tube shunts can result in great outcomes—for the right patients.
By Constance O. Okeke, MD, MSCE
INCLUSION AND DIVERSITY
An exploration of progress and challenges in the field.
By Lisa Brothers Arbisser, MD; Rosa Braga-Mele, MD, MEd, FRCSC; Kendall E. Donaldson, MD, MS; Soosan Jacob, MD, MS, FRCS, DNB; Jennifer Loh, MD; Cynthia Matossian, MD; Marguerite McDonald, MD; Constance O. Okeke, MD, MSCE; Mildred M. G. Olivier, MD; Heather Ready, MBA; and Sarwat Salim, MD
RESIDENTS AND FELLOWS
By Elizabeth Marlow, MD
COVER FOCUS: Script Rewrite
An overview of devices in development.
By Inder Paul Singh, MD
Could an external drug delivery device help knock out noncompliance?
By Brian Flowers, MD
Enhancing adherence to glaucoma therapy with punctal plug drug delivery platforms.
By Malik Y. Kahook, MD; Jeffrey R. SooHoo, MD; and Leonard K. Seibold, MD
Rho kinase inhibitors could shake up glaucoma medical therapy.
By Janet B. Serle, MD
Latanoprostene bunod shows promise.
By Carla J. Siegfried, MD
Could this therapeutic strategy solve some problems?
By Lauren Seo and Nathan Radcliffe, MD
Treating ocular surface disease in glaucoma patients.
By Francis W. Price Jr, MD
THE BACK PAGE
The top five of five.